The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will inject $102.5 million in renewed research funding over seven years for the Antibacterial Resistance Leadership Group (ARLG). This consortium of scientific experts leads a comprehensive clinical research network overseeing important scientific questions related to antibacterial resistance.
TrialSite News breaks down the ARLG and this news.
What is the Antibacterial Resistance Leadership Group (ARLG)?
The ARLG consists of more than 50 leading experts working together to combat antibacterial resistance crisis and improve patient care. They accomplish this goal through a scientific agenda that prioritizes areas of unmet needs, innovates clinical trial design, and informs practice-changing guidelines.
When was it Formed?
Why is it Important?
The Centers for Disease Control and Prevention report that antibacterial resistance is already a serious concern in the nation—for example, more than 35,000 people die in America each year from antibiotic-resistant infections.
Who Funds the ARLG?
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
What is the Leadership?
With leadership facilitated by the Duke Clinical Research Institute, it includes an executive committee and two principal investigators, including Vance Fowler, MD, of Duke University and Henry “Chip” Chambers, MD, University of California, San Francisco
What does the New NIAID-based Funding go to?
The renewed funding from NIAID will provide Duke University, Durham, North Carolina, which will coordinate the ARLG, with support to continue as well as enhance the ARLG’s research activities.
Additionally, under the new grant, the ARLG places continued emphasis on the development of better countermeasures against antibiotic-resistant bacteria. Including a diverse array of innovative, non-antibiotic approaches from vaccines, bacteriophages (viruses that selectively kill bacteria) to approaches that alter a person’s microbiome to fight infection, ARGL will seek to continue its mission creatively and prudently—introducing support for improved diagnostic tests for identifying antibiotic-resistant microbes to supporting the optimization of the use of existing antibiotics.
The ARGL will moving forward include several centers supporting essential network functions:
- The Scientific Leadership Center will provide administrative guidance and oversight, prioritize the research agenda and ensure timely publication of results.
- The Clinical Operations Center will provide clinical support for studies and trials, select sites, oversee protocol teams and ensure that the trials are aligned with ARLG priorities.
- The Laboratory Center will oversee laboratory research and ensure that the specimens from clinical trials are processed, analyzed, and stored appropriately.
- The Statistics and Data Management Center will assist with study design and analysis to ensure high-quality data.
Some of ARGL’s Accomplishments
Since its founding in 2013, the ARLG has established 19 collaborations in 19 countries and conducted more than 40 clinical research studies involving more than 20,000 volunteers (all in 6 years)! ARLG-supported research has led to over 130 research articles on a range of topics, including antimicrobial stewardship and epidemiology, diagnosis and management of infections with antibiotic resistant bacteria.
The ARGL has formed significant value-added partnerships with other major research networks, including the European COMBACTE consortium—super global networks support large studies with dozens of clinical trials sites working in tandem to enroll study volunteers. Large multicenter studies, such as the Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae (CRACKLE), have produced important datasets that have generated new understanding and spurred additional research questions.
Call to Action: Interested in keeping updated with the ARLG? See their contact info.